The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone

European Journal of Clinical Pharmacology

Volumn 66, Issue 11, 2010, Pages 1109-1117

  Jovanović, Nikolina ^a   Božina, Nada ^b   Lovrić, Mila ^b   Medved, Vesna ^a   Jakovljević, Miro ^a   Peleš, Alma Mihaljević ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

9 hydroxirisperidone; ABCB1; CYP2D6; Risperidone; Schizophrenia

Indexed keywords

CYTOCHROME P450 2D6; MULTIDRUG RESISTANCE PROTEIN 1; PALIPERIDONE; RISPERIDONE;

ADULT; AMENORRHEA; ARTICLE; BEDTIME DOSAGE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; EXTRAPYRAMIDAL SYNDROME; FEMALE; GALACTORRHEA; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GYNECOMASTIA; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; WILD TYPE;

ADULT; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; MUTATION; P-GLYCOPROTEIN; PYRIMIDINES; RISPERIDONE; SAMPLE SIZE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 78649326506     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0850-1     Document Type: Article

References (30)

1. MJ Arranz J de Leon 2007 Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research Mol Psychiatry 12 707 747 1:CAS:528:DC%2BD2sXot1Crurc%3D 10.1038/sj.mp.4002009 17549063 (Pubitemid 47172693)
2. M Aravagiri SR Marder D Wirshing WC Wirshing 1998 Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection Pharmacopsychiatry 31 102 109 1:CAS:528:DyaK1cXks1Kjurk%3D 10.1055/s-2007-979308 9657237
3. J Fang M Bourin GB Baker 1999 Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4 Naunyn-Schmiederberg's Arch Pharmacol 359 147 151 1:CAS:528:DyaK1MXkslymtA%3D%3D 10.1007/PL00005334
4. N Yasui-Furukori M Hidestrand E Spina G Facciolà MG Scordo G Tybring 2001 Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes Drug Metab Dispos 29 1263 1268 1:CAS:528:DC%2BD3MXntVGqtbY%3D 11560868
5. SF Zhou 2009 Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I Clin Pharmacokinet 48 689 723 1:CAS:528:DC%2BD1MXhsFOmt7rP 10.2165/11318030-000000000-00000 19817501
6. C Marzolini E Paus T Buclin RB Kim 2004 Polymorphisms in human MDR1 (Pglycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 13 33 1:CAS:528:DC%2BD2cXntVKiuw%3D%3D 10.1016/j.clpt.2003.09.012 14749689 (Pubitemid 38130115)
7. DW Boulton CL DeVane HL Liston JS Markowitz 2002 In vitro P-glycoprotein affinity for atypical and conventional antipsychotics Life Sci 71 163 169 1:CAS:528:DC%2BD38XjvVWjsrg%3D 10.1016/S0024-3205(02)01680-6 12031686 (Pubitemid 34595435)
8. S Hoffmeyer O Burk O von Richter HP Arnold J Brockmoller A Johne I Cascorbi T Gerloff I Roots M Eichelbaum U Brinkmann 2000 Functional polymorphisms of the human multidrug-resistance gene. multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 3473 3478 1:CAS:528: DC%2BD3cXitlWqtL8%3D 10.1073/pnas.050585397 10716719 (Pubitemid 30183327)
9. MG Scordo E Spina G Facciolà A Avenoso I Johansson ML Dahl 1999 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone Psychopharmacology 147 300 305 1:CAS:528: DC%2BD3cXpslKrtg%3D%3D 10.1007/s002130051171 10639689 (Pubitemid 30010551)
10. A Gunes E Spina ML Dahl MG Scordo 2008 ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety Ther Drug Monit 30 628 633 1:CAS:528:DC%2BD1cXht1aisL3O 10.1097/FTD. 0b013e3181858ca9 18708991
11. N Yasui-Furukori K Mihara T Takahata A Suzuki T Nakagami R De Vries T Tateishi T Kondo S Kaneko 2004 Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes Br J Clin Pharmacol 57 569 575 1:CAS:528:DC%2BD2cXksF2ktLg%3D 10.1111/j.1365-2125.2003.02061.x 15089809 (Pubitemid 38582176)
12. World Health Organization (WHO) (1990) International classification of Disease, 10th edn (ICD-10). WHO, Geneva
13. SR Kay A Fiszbein LA Opler 1988 Positive and Negative Symptom Scale (PANSS) for schizophrenia Schizophr Bull 13 21 76
14. GN Simpson JWS Angus 1970 A rating scale for extrapyramidal side effects Acta Psychiatr Scand 212 11 19 1:STN:280:DyaE3c3ptFWjuw%3D%3D 10.1111/j.1600-0447.1970.tb02066.x
15. T Stüven EU Griese HK Kroemer M Eichelbaum UM Zanger 1996 Rapid detection of CYP2D6 null alleles by long distance and multiplex-polymerase chain reaction Pharmacogenetics 6 417 421 10.1097/00008571-199610000-00005 8946473 (Pubitemid 26380097)
16. F Arjomand-Nahad K Diefenbach O Landt E Gaikovitch I Roots 2004 Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes Anal Biochem 334 201 203 1:CAS:528:DC%2BD2cXotF2nsro%3D 10.1016/j.ab.2004.07.030 15464971 (Pubitemid 39304093)
17. K Oselin T Gerloff PM Mrozikiewicz R Pähkla I Roots 2003 MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes Fundam Clin Pharmacol 17 463 469 1:CAS:528:DC%2BD3sXlvFCnt7c%3D 10.1046/j.1472-8206.2003.00163.x 12914549 (Pubitemid 36920648)
18. N von Ahsen M Richter C Grupp B Ringe M Oellerich VW Armstrong 2001 No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients Clin Chem 47 1048 1052
19. N Bozina N Jovanovic M Lovric V Medved 2008 Clinical significance of a CYP2D6 poor metabolizer: a case report of a patient with schizophrenia on risperidone treatment Ther Drug Monit 30 748 751 10.1097/FTD.0b013e3181896afc 18806696
20. HK Roh CE Kim WG Chung CS Park JO Svensson L Bertilsson 2001 Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients Eur J Clin Pharmacol 57 671 675 1:CAS:528:DC%2BD38XltV2itw%3D%3D 10.1007/s002280100372 11791898
21. N Bozina P Granić Z Lalić I Tramisak M Lovrić A Stavljenić-Rukavina 2003 Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population Croat Med J 44 425 428 12950145
22. J de Leon MT Susce RM Pan M Fairchild WH Koch PJ Wedlund 2005 The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation J Clin Psychiatry 66 15 27 10.4088/JCP.v66n0103 15669884
23. S Ito I Ieiri M Tanabe A Suzuki S Higuchi K Otsubo 2001 Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects Pharmacogenetics 11 175 184 1:CAS:528:DC%2BD3MXisFSmtLc%3D 10.1097/00008571-200103000-00008 11266082 (Pubitemid 32216128)
24. R Yoshimura N Ueda J Nakamura 2001 Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study Neuropsychobiology 44 129 133 1:CAS:528:DC%2BD3MXntlGjur0%3D 10.1159/000054932 11586052 (Pubitemid 34701619)
25. E Spina A Avenoso G Facciola M Salemi MG Scordo M Ancione AG Madia E Perucca 2001 Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia Psychopharmacology 153 238 243 1:CAS:528:DC%2BD3MXhtlGiurw%3D 10.1007/s002130000576 11205425 (Pubitemid 32127893)
26. J Leon MT Susce RM Pan PJ Wedlund ML Orrego FJ Diaz 2007 A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels Pharmacopsychiatry 40 93 102 10.1055/s-2007-973836 17541883 (Pubitemid 46910379)
27. Kastelic M, Koprivšek J, Plesničar BK, Serretti A, Mandelli L, Locatelli I, Grabnar I, Dolžan V (2010) MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 34:387-392
28. N Bozina MR Kuzman V Medved N Jovanovic J Sertic L Hotujac 2008 Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients J Psychiatr Res 42 89 97 10.1016/j.jpsychires.2006.10.002 17113599 (Pubitemid 350061252)
29. O Agid S Kapur T Arenovich RB Zipursky 2003 Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected Arch Gen Psychiatry 60 1228 1235 1:CAS:528:DC%2BD2cXhtF2lsw%3D%3D 10.1001/archpsyc.60.12.1228 14662555 (Pubitemid 37494076)
30. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543-1549